<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高解释</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1Vuepj4z_tesaaxkwjxbogotaabxd6u-nvu8003krcpqpqpqpqpqc8ylqc-mmedium = mmedium = rsssssmm_pecce = = = = = = = = = = = = = = = = = = = = = = = rome.sourmem em elome.nylome ew.s 250307091038＆fc = 20230708114047＆utm_content = 1VUEPJ4Z_TESAAXKWJXBOGOTAABXD6U-NVU8003KRCPQ8YLLQCCCC-＆utm_CAMPAIGN = PUBMED-2<description>心血管高额外版：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;ff=20250307091038&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期五，2025年3月7日14:10:39 +0000</lastbuilddate><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>心脏移植中的临床结果与正常热脉冲器官灌注：OCS心脏灌注注册表的报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/40052272/？ 08114047＆ff = 20250307091038＆v = 2.18.0.post9+e462414<description>结论：我们证明，对DBD捐赠者的OCS实施（主要是专门的恢复团队）与扩展的供体标准，更长的运输距离和出色的转移后结果相关联，OCS-DCD捐助者与NRP-DCD和Befored Donor的捐助者相似。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年3月7日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：一个制备系统，器官护理系统（OCS；透射剂）在器官运输过程中使用正常的热脉冲灌注进行心脏移植。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：OCS心脏灌注注册表使用OCS，静态冷藏（SC）或胸腔腹部正常式区域灌注（NRP）收集美国心脏移植的数据，我们从DBD或DCD供体中分析了捐赠者和oct ocs the the thefter ocs and consplant ocs and consplant or consect。捐助者与使用NRP恢复的倾向分数匹配的人相比，用于调整受体特征之间的差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在2021年至2023年之间，在心脏灌注注册表中分析了56个中心的保守性心脏移植。使用NRP技术。 OCS-DBD组在最终接受之前经历了更多的器官拒绝（Wilcoxon等级总和， <i>p</i> &lt;0.001）和更长的运输距离（667英里对232英里； Wilcoxon等级总和， <i>p</i> &lt;0.001），与SCS-DBD相比，SCS-DBD<i>相似</i>。 ）。在OCS-DCD和SCS-DBD组中，12个月的存活率也相似（91.0％和92.5％；边际COX模型， <i>P</i> = 0.32），OCS-DCD和NRP-DCD组显示出相似的生存率（91.0％与91.7％的cocs），尽管cocs conss conss <i>conss</i> conss comply； （400英里与223英里；到2023年，Wilcoxon等级总和<i>p</i> &lt;0.001。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们证明，对DBD捐赠者的OCS实施（主要是专门的恢复团队）与扩展的供体标准，更长的运输距离和出色的转移后结果相关联，OCS-DCD捐助者与NRP-DCD和Befored Donor的捐助者相似。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40052272/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40052272</a> <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071743>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40052272</guid><pubDate> Fri, 07 Mar 2025 06:00:00 -0500</pubDate><dc:creator>约瑟夫·斯特里克（Josef Stehlik）</dc:creator><dc:creator> Maryjane A Farr</dc:creator><dc:creator> Mandeep R Mehra</dc:creator><dc:creator> Jacob N Schroder</dc:creator><dc:creator> David A D&#39;Alessandro</dc:creator><dc:creator>杰伊·D·帕尔</dc:creator><dc:creator>Mauricio A Villavicencio</dc:creator><dc:creator>彼得·格伯（Peter J Gruber）</dc:creator><dc:creator> Gregory S Couper</dc:creator><dc:creator> Yasuhiro Shudo</dc:creator><dc:creator> Parag C Patel</dc:creator><dc:creator> Mani a daneshmand</dc:creator><dc:creator> Liviu Klein</dc:creator><dc:creator> Ashish S Shah</dc:creator><dc:creator>埃里克·R船长</dc:creator><dc:creator>Farded Esmailian</dc:creator><dc:creator>丹尼尔·戈德斯坦</dc:creator><dc:creator>Suguru ohirah</dc:creator><dc:creator>卢西安·洛桑基（Lucian Lozonschi）</dc:creator><dc:creator> David J Kaczorowski</dc:creator><dc:creator>武田小锦鱼</dc:creator><dc:creator>Rajasekhar Sr Malyala</dc:creator><dc:creator>乔纳森·W哈夫</dc:creator><dc:creator>丹·迈尔（Dan M Meyer）</dc:creator><dc:creator>本杰明·C太阳</dc:creator><dc:creator>Victor Pretorius</dc:creator><dc:creator>阿尔曼·基利奇（Arman Kilic）</dc:creator><dc:creator> Anelechi C Anyanwu</dc:creator><dc:creator>塞莱斯特·威廉姆斯</dc:creator><dc:creator>duc t pham</dc:creator><dc:creator> Masashi Kai</dc:creator><dc:creator> Nasir Z Sulemanjee</dc:creator><dc:creator> Akinobu Itoh</dc:creator><dc:creator> Masaki Funamoto</dc:creator><dc:creator>克里斯托弗·萨勒诺（Christopher T Salerno）</dc:creator><dc:creator> John S Ikonomidis</dc:creator><dc:creator>露西安·达勒姆（Lucian A Durham）</dc:creator><dc:creator>安德鲁·谢弗（Andrew Shaffer）</dc:creator><dc:creator>西安周</dc:creator><dc:creator>法汉·扎法尔（Farhan Zafar）</dc:creator><dc:creator>肖恩·普莱尼（Sean P Pinney）</dc:creator><dc:creator> Carmelo A Milano</dc:creator><dc:date> 2025-03-07</dc:date><dc:source>循环</dc:source><dc:title>心脏移植中的临床结果与正常热脉冲器官灌注：OCS心脏灌注注册表的报告</dc:title><dc:identifier>PMID：40052272</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.071743</dc:identifier></item><item><title>澳大利亚新西兰自发冠状动脉解剖队列研究：主要不良心血管事件和复发的预测因子</title><link/>https://pubmed.ncbi.nlm.nih.gov/40049585/？ 08114047＆ff = 20250307091038＆v = 2.18.0.post9+e462414<description>结论：研究结果支持以下假设：SCAD主要是由壁内出血引起的，其潜在的抗血小板疗法和抗凝性和抗凝性和不良心血管结局的有害关联。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 3月7日：EHAF097：10.1093/Eurheartj/ehaf097。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：自发的冠状动脉解剖（SCAD）是急性冠状动脉综合征的越来越多的原因（ACS）表明，与SCAD相比，与单个抗血小板疗法相比，双重抗血小板疗法有害。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这项涉及23个澳大利亚和新西兰地点的多中心队列研究包括≥18岁的患者，因为SCAD在核心实验室调整中确认了ACS。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在586名患者中，有505例（150个前瞻性，355个回顾性）通过核心实验室调整确认，平均年龄为52.2±10.6岁，女性为88.6％，在长期随访（中间21个月），MACE和SCAD复发是在8.6％和3.6％的患者中。 3.8，95％的置信区间（CI）1.6-9.3，p = .003]，ticagrelor与阿司匹林结合（AHR 1.8，95％CI 1.04-3.2，p = .037），纤维肌发育不良， 03）与较高的MACE独立相关3.9，95％CI 1.5-26.5，p = .01），ticagrelor与阿司匹林结合（AHR 2.6，95％CI 2.1-5.3，p = .01），中风病史（AHR 6.2，95％CI 1.8-9.5，p = .01）也与较高的SCAD复发相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：研究结果支持以下假设：SCAD主要是由壁内出血引起的，其潜在的抗血小板疗法和抗凝性和抗凝性和不良心血管结局的有害关联。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40049585/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40049585</a> <a href=https://doi.org/10.1093/eurheartj/ehaf097>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40049585</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> quan m dang</dc:creator><dc:creator>彼得·J·帕斯蒂斯（Peter J Psaltis）</dc:creator><dc:creator>索尼娅·伯吉斯（Sonya Burgess）</dc:creator><dc:creator> Jaya Chandrasekhar</dc:creator><dc:creator> Swati Mukherjee</dc:creator><dc:creator>伦纳德·克里萨里德斯（Leonard Kritharides）</dc:creator><dc:creator>奈杰尔·杰普森（Nigel Jepson）</dc:creator><dc:creator>莎拉·费尔利（Sarah Fairley）</dc:creator><dc:creator> Abdul Ihdayhid</dc:creator><dc:creator>杰米·拉兰（Jamie Layland）</dc:creator><dc:creator>理查德·塞尔特（Richard Szirt）</dc:creator><dc:creator> Seif El-Jack</dc:creator><dc:creator> Aniket Puri</dc:creator><dc:creator>以斯帖·戴维斯（Esther Davis）</dc:creator><dc:creator> Imran Shiekh</dc:creator><dc:creator>露丝·阿诺德（Ruth Arnold）</dc:creator><dc:creator> Monique Watts</dc:creator><dc:creator>杰西卡（Jessica A Marathe）</dc:creator><dc:creator> Rohan Bhagwandeen</dc:creator><dc:creator> Edwina Wing-Lun</dc:creator><dc:creator> Ravinay Bhindi</dc:creator><dc:creator>汤姆·福特</dc:creator><dc:creator>西德尼·卢（Sidney Lo）</dc:creator><dc:creator>西蒙妮·马希纳（Simone Marschner）</dc:creator><dc:creator>莎拉·扎曼（Sarah Zaman）</dc:creator><dc:date> 2025-03-06</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>澳大利亚新西兰自发冠状动脉解剖队列研究：主要不良心血管事件和复发的预测因子</dc:title><dc:identifier>PMID：40049585</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf097</dc:identifier></item><item><title> Cyoeleclectron断层扫描中完整组织中Copia逆转座子的细胞内结构和快照</title><link/>https://pubmed.ncbi.nlm.nih.gov/40049165/？ 08114047＆ff = 20250307091038＆v = 2.18.0.post9+e462414<description>长时间重复（LTR）循环座位属于可替代的元素（TES），自主复制遗传元素在动物中融合到宿主的基因组中研究，我们使用以低温为中心的离子束（FIB）铣削和拔出... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 3月3<b>日</b>。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">长时间重复（LTR）循环座位属于可替代的元素（TES），自主复制遗传元素在动物中融合到宿主的基因组中研究，我们使用cryo-focused ion beam (FIB) milling and lift-out approaches to visualize copia VLPs in ovarian cells and intact egg chambers, resolving the in situ copia capsid structure to 7.7 Å resolution by cryoelectron tomography (cryo-ET). Although cytoplasmic copia VLPs vary in size, nuclear VLPs are homogeneous and form desely packed clusters, supporting a model in which nuclear import acts as a size selector. Analyzing flies deficient in the Te抑制Piwi相互作用的RNA（PIRNA）途径，我们在精子发生过程中观察到Copia的易位到细胞核中。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40049165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40049165</a> <a href=https://doi.org/10.1016/j.cell.2025.02.003>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40049165</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Sven Klumpe</dc:creator><dc:creator> Kirsten A Senti</dc:creator><dc:creator>弗洛里安·贝克（Florian Beck）</dc:creator><dc:creator>珍妮·萨克韦（Jenny Sachweh）</dc:creator><dc:creator>伯恩哈德·汉波尔兹（Bernhard Hampoelz）</dc:creator><dc:creator>保罗·罗奇（Paolo Ronchi）</dc:creator><dc:creator> Viola Oorschot</dc:creator><dc:creator> Marlene Brandstetter</dc:creator><dc:creator> Assa Yerostlaviz</dc:creator><dc:creator>约翰·阿布里格斯（John Ag Briggs）</dc:creator><dc:creator>朱利叶斯·布伦内克（Julius Brennecke）</dc:creator><dc:creator>马丁·贝克</dc:creator><dc:creator>JürgenM Plitzko</dc:creator><dc:date> 2025-03-06</dc:date><dc:source>细胞</dc:source><dc:title>Cyoeleclectron断层扫描中完整组织中Copia逆转座子的细胞内结构和快照</dc:title><dc:identifier>PMID：40049165</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.02.003</dc:identifier></item><item><title> CXCL12驱动冠状动脉解剖学的自然变异</title><link/>https://pubmed.ncbi.nlm.nih.gov/40049164/？ 08114047＆ff = 20250307091038＆v = 2.18.0.post9+e462414<description>冠状动脉在人类中具有特定的分支模式。中度遗传力和... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 3月3<b>日</b>。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">冠状动脉在人类中具有特定的分支模式。中度Heritability and identifying ten significant locale. The strong association occurred near CXCL12 in both European- and African-ancestry cohorts, with downstream analyses implicit effects on CXCL12 expression. We show that CXCL12 is expressed in human fetal hearts at the time dominance is established. Reducing Cxcl12 in mice altered coronary dominance and caused septal arteries to develop away from Cxcl12 expression domains. These findings表明CXCL12模式人类冠状动脉，通过靶向发育途径为“医学血运重建”铺平了道路。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40049164/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40049164</a> <a href=https://doi.org/10.1016/j.cell.2025.02.005>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40049164</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator>帕梅拉·里奥斯·科罗纳多</dc:creator><dc:creator>斋扬周</dc:creator><dc:creator>小粉丝</dc:creator><dc:creator>Daniela Zanetti</dc:creator><dc:creator>杰弗里（Jeffrey）naftaly</dc:creator><dc:creator> Pratima Prabala</dc:creator><dc:creator> AzaliaMartínezJ​​aimes</dc:creator><dc:creator> Elie N Farah</dc:creator><dc:creator> Soumya Kundu</dc:creator><dc:creator> Salil S Deshpande</dc:creator><dc:creator>常春藤常绿</dc:creator><dc:creator>Pik Fang Kho</dc:creator><dc:creator> Qixuan MA</dc:creator><dc:creator>奥斯汀·希利亚德（Austin T Hilliard）</dc:creator><dc:creator>莎拉·阿布拉莫维茨（Sarah Abramowitz）</dc:creator><dc:creator> Saiju Pyarajan</dc:creator><dc:creator>丹尼尔·多奇特曼（Daniel Dochtermann）</dc:creator><dc:creator>百万退伍军人计划</dc:creator><dc:creator>斯科特·M·达姆劳尔（Scott M Damrauer）</dc:creator><dc:creator> Kyong-Mi Chang</dc:creator><dc:creator>迈克尔·莱文（Michael G Levin）</dc:creator><dc:creator>弗吉尼亚D温恩</dc:creator><dc:creator>Anca MPaşca</dc:creator><dc:creator>玛丽E Plomondon</dc:creator><dc:creator>斯蒂芬·沃尔多（Stephen W Waldo）</dc:creator><dc:creator>菲利普·S·托索（Philip S Tsao）</dc:creator><dc:creator> Anshul Kundaje</dc:creator><dc:creator> Neil C Chi</dc:creator><dc:creator> Shoa L Clarke</dc:creator><dc:creator>克里斯蒂红马</dc:creator><dc:creator>Themistocles l Assimes</dc:creator><dc:date> 2025-03-06</dc:date><dc:source>细胞</dc:source><dc:title>CXCL12驱动冠状动脉解剖学的自然变异</dc:title><dc:identifier>PMID：40049164</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.02.005</dc:identifier></item><item><title>普通和发散的细胞病因是左心脏综合征和低塑性右心脏综合征的基础疾病</title><link/>https://pubmed.ncbi.nlm.nih.gov/40048662/？ 08114047＆ff = 20250307091038＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 3月6日：EHAF121。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40048662/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40048662</a> <a href=https://doi.org/10.1093/eurheartj/ehaf121>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40048662</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator>杨</dc:creator><dc:creator>Cankun Wang</dc:creator><dc:creator> shiqiao ye</dc:creator><dc:creator>汉娜秦</dc:creator><dc:creator>马修·阿隆佐（Matthew Alonzo）</dc:creator><dc:creator> Angela Onorato</dc:creator><dc:creator>亚伦·阿尔尔（Aaron Argall）</dc:creator><dc:creator>凯伦·德克萨斯（Karen Texter）</dc:creator><dc:creator>秦马</dc:creator><dc:creator>Vidu Garg</dc:creator><dc:creator>明 - 陶赵</dc:creator><dc:date>2025-03-06</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>普通和发散的细胞病因是左心脏综合征和右心脏综合征的基础疾病</dc:title><dc:identifier>PMID：40048662</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf121</dc:identifier></item><item><title>恢复BCIS2和Stiches中的医疗疗法和结果：单个患者数据分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/40048661/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description>结论：在复兴的BCIS2中接受药物治疗的缺血性心肌病患者比在CABG手术中进行的cabg，PCI和医疗疗法的进一步试验的结果更好。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 3月6日：EHAF080：10.1093/Eurheartj/ehaf080。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: In the Surgical Treatment for Ischaemic Heart Failure Trial Extension Study (STICHES), coronary artery bypass grafting (CABG) improved outcomes of patients with ischaemic left ventricular dysfunction receiving medical therapy, whereas in the Revascularization for Ischaemic Ventricular Dysfunction trial (REVIVED-BCIS2), percutaneous coronary intervention (PCI) did not. The aim of this study是为了探索仅在Stiches与Revived-BCIS2中仅接受药物疗法治疗的参与者的结果差异，并评估CABG或PCI的增量益处。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对两个多中心随机试验的调整后的数据进行了汇总分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：包括1912名参与者（男性为88％，白人种族76％），主要结果的随访时间为98.3％。置信区间0.48-0.74，p &lt;.001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在复兴的BCIS2中接受药物治疗的缺血性心肌病患者比在CABG手术中进行的cabg，PCI和医疗疗法的进一步试验的结果更好。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40048661/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40048661</a> <a href=https://doi.org/10.1093/eurheartj/ehaf080>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40048661</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator>马修·瑞安（Matthew Ryan）</dc:creator><dc:creator>马克·佩特里（Mark C Petrie）</dc:creator><dc:creator> Evangelos Kontopantelis</dc:creator><dc:creator>马修·多德（Matthew Dodd）</dc:creator><dc:creator>广孔</dc:creator><dc:creator>Guillaume Marquis-Gravel</dc:creator><dc:creator> Kieran F Docherty</dc:creator><dc:creator>蒂姆·克莱顿（Tim Clayton）</dc:creator><dc:creator>亚历山德拉·J·兰斯基（Alexandra J Lansky）</dc:creator><dc:creator>妈妈A妈妈</dc:creator><dc:creator>让·卢西安·鲁劳（Jean-Lucien Rouleau）</dc:creator><dc:creator> Eric J Velazquez</dc:creator><dc:creator> Divaka Perera</dc:creator><dc:date> 2025-03-06</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>恢复BCIS2和Stiches中的医疗疗法和结果：单个患者数据分析</dc:title><dc:identifier>PMID：40048661</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf080</dc:identifier></item><item><title> SLC31A1损失耗尽线粒体铜并促进心脏纤维化</title><link/>https://pubmed.ncbi.nlm.nih.gov/40048660/？ 08114047＆ff = 20250307091038＆v = 2.18.0.post9+e462414<description>结论：一种新型的表观遗传机制通过，铜缺乏增加线粒体铜的耗竭并损害CF。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 3月6日：EHAF130：10.1093/Eurheartj/ehaf130。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：金属作为涉及线粒体代谢重新编程的大量金属酶的辅助因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用电感耦合的血浆质谱法测量小鼠心脏样品的金属含量。给予四酸糖氢以研究其在CF中的重要作用。 Histological and biochemical analyses were performed to determine how YTHDF1/MeCP2 regulated SLC31A1 expression in CF. The reconstitution of SLC31A1 in YTHDF1/MeCP2-deficiency cardiac fibroblasts and mouse hearts was performed to study its effect on mitochondrial copper deployment and fibrosis. Human heart tissues from atrial fibrillation patients were used to validate the findings. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：较低的铜浓度是通过CF中的SLC31A1下调和线粒体铜的部署。启动子区域中的SLC31A1相反，限制了其转录。 MECP2返回的SLC31A1表达，导致MECP2上调与M6A mRNA水平升高有关，YTHDF1识别目标MECP2 mRNA，并诱导其在人心脏组织中的转化。这些变化与线粒体铜的部署，增强的糖酵解和CF有关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：一种新型的表观遗传机制通过，铜缺乏增加线粒体铜的耗竭并损害CF。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40048660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40048660</a> <a href=https://doi.org/10.1093/eurheartj/ehaf130>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40048660</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> bin tu</dc:creator><dc:creator>凯歌</dc:creator><dc:creator>Ze-Yu Zhou</dc:creator><dc:creator> Li-chan lin</dc:creator><dc:creator> Zhi-Yan Liu</dc:creator><dc:creator>他太阳</dc:creator><dc:creator>杨周</dc:creator><dc:creator>吉 - 敏莎</dc:creator><dc:creator>YAN SHI</dc:creator><dc:creator> Jing-jing Yang</dc:creator><dc:creator>你们张</dc:creator><dc:creator>Jian-Yuan Zhao</dc:creator><dc:creator> Hui Tao</dc:creator><dc:date> 2025-03-06</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>SLC31A1损失耗尽线粒体铜并促进心脏纤维化</dc:title><dc:identifier>PMID：40048660</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf130</dc:identifier></item><item><title>缺少“ LNCS”：审查不足会导致长期非编码RNA（LNCRNA）及其在心血管疾病中的功能差异</title><link/>https://pubmed.ncbi.nlm.nih.gov/40048659/？ 08114047＆ff = 20250307091038＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 3月6日：EHAF115：10.1093/Eurheartj/ehaf115。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40048659/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40048659</a> <a href=https://doi.org/10.1093/eurheartj/ehaf115>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40048659</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator>马修·贝内特（Matthew Bennett）</dc:creator><dc:creator>伊戈尔·乌利茨基</dc:creator><dc:creator>安德鲁·贝克（Andrew H Baker）</dc:creator><dc:date> 2025-03-06</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>缺少“ LNCS”：审查不足会导致长期非编码RNA（LNCRNA）及其在心血管疾病中的功能差异</dc:title><dc:identifier>PMID：40048659</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf115</dc:identifier></item><item><title> lncRNA miR181A1Hg缺乏减弱血管炎症和动脉粥样硬化</title><link/>https://pubmed.ncbi.nlm.nih.gov/40047069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description>结论：这些发现将MiR181A1HG视为动脉粥样硬化中血管性感染的核心驱动因素，它可以将FOXP1从靶基因启动子中驱逐并激活NLRP3炎症体在我们的研究中，我们的研究表明MiR181A1HG是对未来病毒性疾病的靶向靶标的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res。2025年3月6日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：内皮细胞（EC）功能障碍和血管感染在动脉粥样硬化的起始和进展中至关重要。研究旨在研究MIR181A1HG在控制血管炎症中的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们检查了MiR181A1Hg在人类和小鼠<sup>动脉</sup>粥样硬化病变中的表达。 <sup>ED</sup>与单细胞RNA结合测序。通过荧光素酶报告基因和染色质免疫沉淀测定，MIR181A1HG的转录调节。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：MiR181A1Hg在EC中的表达很大，在人和<sup>小鼠</sup>动脉粥样硬化<sup>病变</sup>中显着增加。 OID销售不会改变动脉粥样硬化的进展测序分析表明，MiR181A1HG缺乏症减少了动脉粥样硬化病变中EC簇中的免疫菌株的比例和富集的抗炎途径。 CC950）。 NF-κB（核因子KAPPA B）/p65依赖性途径。由miR181A1HG删除介导的效果体内。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些发现将MiR181A1HG视为动脉粥样硬化中血管性感染的核心驱动因素，它可以将FOXP1从靶基因启动子中驱逐并激活NLRP3炎症体在我们的研究中，我们的研究表明MiR181A1HG是对未来病毒性疾病的靶向靶标的。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40047069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40047069</a> <a href=https://doi.org/10.1161/CIRCRESAHA.124.325196>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40047069</guid><pubDate> Thu, 06 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Huaner ni</dc:creator><dc:creator> Yulong GE</dc:creator><dc:creator> Ying Zhuge</dc:creator><dc:creator>小刘刘</dc:creator><dc:creator>Hangwei Chen</dc:creator><dc:creator> Junyi Liu</dc:creator><dc:creator> Weifeng Li</dc:creator><dc:creator>徐王</dc:creator><dc:creator>古山</dc:creator><dc:creator>王王</dc:creator><dc:creator>Rulin Zhuang</dc:creator><dc:creator>马克·弗恩伯格</dc:creator><dc:creator>方王</dc:creator><dc:date>2025-03-06</dc:date><dc:source>循环研究</dc:source><dc:title>lncRNA miR181A1Hg缺乏减弱血管炎症和动脉粥样硬化</dc:title><dc:identifier>PMID：40047069</dc:identifier><dc:identifier> doi：10.1161/circresaha.124.325196</dc:identifier></item><item><title>心血管稳态和疾病的细胞外蔬菜：诊断和治疗中的潜在作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/40045042/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description>在过去的十年中，多细胞器官之间的沟通是传播信号的，细胞外蔬菜在物理和病理环境中的分子通信中的作用至关重要。不同的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在过去的十年中，多细胞器官之间的沟通是传播信号的，细胞外蔬菜在物理和病理环境中的分子通信中的作用至关重要。不同的细胞外蔬菜亚类及其异质性，可以在心血管系统中介绍细胞外蔬菜介导的信号传导，并突出显示细胞外蔬菜如何用作诊断和预后的生物标志物，以便最终讨论各种病理学的植物。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40045042/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40045042</a> <a href=https://doi.org/10.1038/s41569-025-01141-2>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40045042</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Junjie Xiao</dc:creator><dc:creator> JOOST PG SLUIJTER</dc:creator><dc:date> 2025-03-05</dc:date><dc:source>自然评论</dc:source><dc:title>心血管稳态和疾病的细胞外蔬菜：诊断和治疗中的潜在作用</dc:title><dc:identifier>PMID：40045042</dc:identifier><dc:identifier> doi：10.1038/s41569-025-01141-2</dc:identifier></item><item><title>更正</title><link/>https://pubmed.ncbi.nlm.nih.gov/40044301/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40044301/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40044301</a> <a href=https://doi.org/10.1016/j.jacc.2025.01.003>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40044301</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:date> 2025-03-05</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>更正</dc:title><dc:identifier>PMID：40044301</dc:identifier><dc:identifier> doi：10.1016/j.jacc.2025.01.003</dc:identifier></item><item><title>更正</title><link/>https://pubmed.ncbi.nlm.nih.gov/40044300/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40044300/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40044300</a> <a href=https://doi.org/10.1016/j.jacc.2025.01.010>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40044300</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:date> 2025-03-05</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>更正</dc:title><dc:identifier>PMID：40044300</dc:identifier><dc:identifier> doi：10.1016/j.jacc.2025.01.010</dc:identifier></item><item><title>经导管主动脉瓣置换超出严重主动脉狭窄：JACC最先进的评论</title><link/>https://pubmed.ncbi.nlm.nih.gov/40044299/？ 08114047＆ff = 20250307091038＆v = 2.18.0.post9+e462414<description>症状的替代瓣膜（TAVR）已成为症状严重的主动脉狭窄的患者（AS）的首选治疗方法（AS）。作为早期阀门更换可能会防止不可逆转... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAM Coll Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">症状的替代瓣膜（TAVR）已成为症状严重的主动脉狭窄的患者（AS）的首选治疗方法（AS）。作为早期阀门更换可以防止不可逆的心脏改造。患者池进行此最小侵入性程序。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40044299/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40044299</a> <a href=https://doi.org/10.1016/j.jacc.2024.11.051>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40044299</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Frans J Beerkens</dc:creator><dc:creator>吉尔伯特·HL唐</dc:creator><dc:creator>Annapoorna S Kini</dc:creator><dc:creator> Stamatios Lerakis</dc:creator><dc:creator>乔治·D·丹斯（George D Dangas）</dc:creator><dc:creator> Roxana Mehran</dc:creator><dc:creator> Sahil Khera</dc:creator><dc:creator>马丁·高盛</dc:creator><dc:creator>Valentin Fuster</dc:creator><dc:creator> Deepak L Bhatt</dc:creator><dc:creator>约翰·G·韦伯</dc:creator><dc:creator>Samin K Sharma</dc:creator><dc:date> 2025-03-05</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>经导管主动脉瓣置换超出严重主动脉狭窄：JACC最先进的评论</dc:title><dc:identifier>PMID：40044299</dc:identifier><dc:identifier> doi：10.1016/j.jacc.2024.11.051</dc:identifier></item><item><title>经导管与外科主动脉瓣替代较低风险患者的长期结局：我们还在吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/40044298/？ 08114047＆ff = 20250307091038＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40044298/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40044298</a> <a href=https://doi.org/10.1016/j.jacc.2025.01.020>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40044298</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator>约书亚·沃拉赫（Joshua d Wallach）</dc:creator><dc:creator>大卫·科恩（David J Cohen）</dc:creator><dc:date> 2025-03-05</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>经导管与外科主动脉瓣替代较低风险患者的长期结局：我们还在吗？</dc:title><dc:identifier> PMID：40044298</dc:identifier><dc:identifier> doi：10.1016/j.jacc.2025.01.020</dc:identifier></item><item><title> Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials</title><link/> https://pubmed.ncbi.nlm.nih.gov/40044297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: In lower-risk patients, TAVR was associated with a reduced hazard of death and death or disabling stroke compared with SAVR, while rates of stroke were equivalent. Most patients have not yet undergone 5-year follow-up, and so these findings may change as further longer-term data become available. The present data are informative for lower-risk patients and treating clinicians, but further randomized trials and longer-term follow-up are required, particularly in younger patients. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 11;85(9):926-940. doi: 10.1016/j.jacc.2024.12.031.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Longer-term outcomes are especially important for lower-risk patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Additional randomized data comparing TAVR and SAVR have recently become available. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The purpose of this study was to perform an updated systematic review with conventional pairwise meta-analyses and pooled survival analyses using reconstructed time-to-event individual participant data (IPD) including the totality of randomized evidence comparing longer-term clinical outcomes after TAVR and SAVR in lower-risk patients. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The prespecified primary endpoint was all-cause death. Key secondary endpoints included stroke and the composite of death or disabling stroke. Cox proportional hazards frailty regression and restricted mean survival time models were fitted using reconstructed time-to-event IPD. In sensitivity analyses, proportional odds models were fitted with frailty terms. Conventional pairwise meta-analyses were performed under random and fixed effects assumptions. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Six trials enrolling 5,341 lower-risk patients were included with 2,717 randomized to TAVR and 2,624 randomized to SAVR (weighted mean follow-up of 35.7 months). At 5 years in the pooled survival analyses of reconstructed time-to-event IPD, TAVR was associated with a 20% reduction in the hazard of all-cause death (HR: 0.80; 95% CI: 0.66-0.97; P = 0.02) and a 19% reduction in the hazard of all-cause death or disabling stroke (HR: 0.81; 95% CI: 0.68-0.96; P = 0.01) compared with SAVR. There was no difference in stroke (HR: 0.97; 95% CI: 0.74-1.26; P = 0.80). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: In lower-risk patients, TAVR was associated with a reduced hazard of death and death or disabling stroke compared with SAVR, while rates of stroke were equivalent. Most patients have not yet undergone 5-year follow-up, and so these findings may change as further longer-term data become available. The present data are informative for lower-risk patients and treating clinicians, but further randomized trials and longer-term follow-up are required, particularly in younger patients.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40044297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40044297</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2024.12.031>10.1016/j.jacc.2024.12.031</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40044297</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Rohin K Reddy</dc:creator><dc:creator> James P Howard</dc:creator><dc:creator> Michael J Mack</dc:creator><dc:creator> Michael J Reardon</dc:creator><dc:creator> Troels Højsgaard Jørgensen</dc:creator><dc:creator> Hans Gustav Hørsted Thyregod</dc:creator><dc:creator> William D Toff</dc:creator><dc:creator> Nicolas M Van Mieghem</dc:creator><dc:creator> Amit N Vora</dc:creator><dc:creator> Raj R Makkar</dc:creator><dc:creator> Samir Kapadia</dc:creator><dc:creator> John K Forrest</dc:creator><dc:creator> Martin B Leon</dc:creator><dc:creator> Yousif Ahmad</dc:creator><dc:date> 2025-03-05</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials</dc:title><dc:identifier> pmid:40044297</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2024.12.031</dc:identifier></item><item><title> Navigating the Landscape of Reinterventions After TAVR</title><link/> https://pubmed.ncbi.nlm.nih.gov/40044296/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 11;85(9):908-911. doi: 10.1016/j.jacc.2024.12.018.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40044296/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40044296</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2024.12.018>10.1016/j.jacc.2024.12.018</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40044296</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Gilbert HL Tang</dc:creator><dc:creator> Syed Zaid</dc:creator><dc:creator> Ole De Backer</dc:creator><dc:date> 2025-03-05</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Navigating the Landscape of Reinterventions After TAVR</dc:title><dc:identifier> pmid:40044296</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2024.12.018</dc:identifier></item><item><title> Predictors of Outcomes of Reintervention After Transcatheter Aortic Valve Replacement: FRANCE 2 and FRANCE TAVI Registries</title><link/> https://pubmed.ncbi.nlm.nih.gov/40044295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Reintervention after TAVR remains rare and was mostly performed early after the procedure and by redo TAVR. Further studies are warranted, particularly in younger patients with longer life expectancy. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 11;85(9):896-907. doi: 10.1016/j.jacc.2024.11.048.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: In a context of extending transcatheter aortic valve replacement (TAVR) to patients with a longer life expectancy, it is important to better document the incidence and outcomes of reintervention. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The authors sought to evaluate the incidence, predictive factors, and long-term outcomes of surgical (explant TAVR) or transcatheter (redo TAVR) reintervention after TAVR. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Patients who had a TAVR between 2010 and 2022 recorded in the FRANCE 2 and FRANCE TAVI registries were included in the analysis. Cumulative incidence of early (≤1 year) and late (>;1 year) reintervention was assessed using the Kalbfleisch and Prentice method to account for all-cause death as a competing risk. Patients who had reintervention for infective endocarditis were excluded. Long-term mortality was evaluated using Kaplan-Meier analysis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 72,850 patients included, the cumulative incidence of overall reintervention at 8 years was 1.7% including 591 patients who had redo TAVR and 111 patients who required explant TAVR with a low incidence of Bentall intervention. Reintervention occurred mostly early in 62.1% of cases and was more frequent in patients who had a mean aortic gradient >;20 mm Hg immediately after index TAVR. Age and mean aortic gradient before TAVR and mean aortic gradient >;20 mm Hg, aortic regurgitation ≥ grade 2, and percutaneous coronary intervention after TAVR were predictive of reintervention. Six-year mortality was high but was similar in patients who had early and late reintervention (76.2% vs 64.0%; P = 0.77). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Reintervention after TAVR remains rare and was mostly performed early after the procedure and by redo TAVR. Further studies are warranted, particularly in younger patients with longer life expectancy.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40044295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40044295</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2024.11.048>10.1016/j.jacc.2024.11.048</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40044295</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Eric Durand</dc:creator><dc:creator> Hélène Eltchaninoff</dc:creator><dc:creator> Didier Tchetche</dc:creator><dc:creator> Thomas Levesque</dc:creator><dc:creator> Christian Garmendia</dc:creator><dc:creator> Bernard Iung</dc:creator><dc:creator> Hakim Benamer</dc:creator><dc:creator> Guillaume Cayla</dc:creator><dc:creator> Eric Van Belle</dc:creator><dc:creator> Philippe Commeau</dc:creator><dc:creator> Herve Le Breton</dc:creator><dc:creator> Thomas Cuisset</dc:creator><dc:creator> Mariama Akodad</dc:creator><dc:creator> Jean-Philippe Verhoye</dc:creator><dc:creator> Sylvain Beurtheret</dc:creator><dc:creator> Florence du Chayla</dc:creator><dc:creator> Manon Leclere</dc:creator><dc:creator> Martine Gilard</dc:creator><dc:creator> Nicolas Dumonteil</dc:creator><dc:creator> STOP-AS and France TAVI Investigators</dc:creator><dc:date> 2025-03-05</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Predictors of Outcomes of Reintervention After Transcatheter Aortic Valve Replacement: FRANCE 2 and FRANCE TAVI Registries</dc:title><dc:identifier> pmid:40044295</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2024.11.048</dc:identifier></item><item><title> The Evolving Landscape of TAVR: A JACC Themed Issue</title><link/> https://pubmed.ncbi.nlm.nih.gov/40044294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 11;85(9):875-877. doi: 10.1016/j.jacc.2025.01.021.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40044294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40044294</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2025.01.021>10.1016/j.jacc.2025.01.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40044294</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Aakriti Gupta</dc:creator><dc:creator> Harlan M Krumholz</dc:creator><dc:date> 2025-03-05</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> The Evolving Landscape of TAVR: A JACC Themed Issue</dc:title><dc:identifier> pmid:40044294</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2025.01.021</dc:identifier></item><item><title> Mapping the landscape of social behavior</title><link/> https://pubmed.ncbi.nlm.nih.gov/40043703/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description> Social interaction is integral to animal behavior. However, lacking tools to describe it in quantitative and rigorous ways has limited our understanding of its structure, underlying principles, and the neuropsychiatric disorders, like autism, that perturb it. Here, we present a technique for high-resolution 3D tracking of postural dynamics and social touch in freely interacting animals, solving the challenging subject occlusion and part-assignment problems using 3D geometric reasoning, graph... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2025 Feb 28:S0092-8674(25)00154-0. doi: 10.1016/j.cell.2025.01.044. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Social interaction is integral to animal behavior. However, lacking tools to describe it in quantitative and rigorous ways has limited our understanding of its structure, underlying principles, and the neuropsychiatric disorders, like autism, that perturb it. Here, we present a technique for high-resolution 3D tracking of postural dynamics and social touch in freely interacting animals, solving the challenging subject occlusion and part-assignment problems using 3D geometric reasoning, graph neural networks, and semi-supervised learning. We collected over 110 million 3D pose samples in interacting rats and mice, including seven monogenic autism rat lines. Using a multi-scale embedding approach, we identified a rich landscape of stereotyped actions, interactions, synchrony, and body contacts. This high-resolution phenotyping revealed a spectrum of changes in autism models and in response to amphetamine not resolved by conventional measurements. Our framework and large library of interactions will facilitate studies of social behaviors and their neurobiological underpinnings.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40043703/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40043703</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2025.01.044>10.1016/j.cell.2025.01.044</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40043703</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Ugne Klibaite</dc:creator><dc:creator> Tianqing Li</dc:creator><dc:creator> Diego Aldarondo</dc:creator><dc:creator> Jumana F Akoad</dc:creator><dc:creator> Bence P Ölveczky</dc:creator><dc:creator> Timothy W Dunn</dc:creator><dc:date> 2025-03-05</dc:date><dc:source>细胞</dc:source><dc:title>Mapping the landscape of social behavior</dc:title><dc:identifier> pmid:40043703</dc:identifier><dc:identifier> doi:10.1016/j.cell.2025.01.044</dc:identifier></item><item><title> Filling the Evidence Gaps Toward a Coronary Artery Calcium-Guided Primary Prevention Strategy</title><link/> https://pubmed.ncbi.nlm.nih.gov/40042967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2025.0410. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40042967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40042967</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2025.0410>10.1001/jamacardio.2025.0410</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40042967</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Michael J Blaha</dc:creator><dc:date> 2025-03-05</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Filling the Evidence Gaps Toward a Coronary Artery Calcium-Guided Primary Prevention Strategy</dc:title><dc:identifier> pmid:40042967</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2025.0410</dc:identifier></item><item><title> Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF</title><link/> https://pubmed.ncbi.nlm.nih.gov/40042880/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250307091038&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS AND RELEVANCE: Results of the FINEARTS-HF randomized clinical trial demonstrate that the PREDICT-HFpEF models performed well in terms of calibration and discrimination. Baseline risk did not modify the benefit of finerenone. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2025 Mar 5:e250025. doi: 10.1001/jamacardio.2025.0025. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) have a spectrum of risk, and the effect of therapies may vary by risk. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: To validate the Prognostic Models for Mortality and Morbidity in HFpEF (PREDICT-HFpEF) in the phase 3 randomized clinical trial Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) and to evaluate the effect of finerenone, compared with placebo, across the spectrum of risk in these patients. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: The FINEARTS-HF trial was conducted across 653 sites in 37 countries. Participants were adults 40 years and older with symptomatic HF and left ventricular EF of 40% or greater randomized between September 2020 and January 2023. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTERVENTION: Finerenone (titrated to 20 mg or 40 mg) or placebo. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: The 3 PREDICT-HFpEF risk scores for the composite outcome of cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death, respectively, were calculated. Predicted risk was compared with observed outcomes. Model performance was assessed using the Harrell C statistic. The rates of the predicted outcomes (plus the composite of cardiovascular death and worsening HF events, which was the primary end point in the trial) were examined according to quintiles of risk score, as was the effect of finerenone according to risk quintiles. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 6001 patients (mean [SD] age, 72 [9.6] years; 3269 male [54.5%]) were randomized in the FINEARTS-HF trial. The C statistics for cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death at 2 years were 0.71 (95% CI, 0.69-0.72), 0.68 (95% CI, 0.66-0.71), and 0.69 (95% CI, 0.67-0.71), respectively. The risk of the composite outcomes was approximately 8- to 10-fold higher in those in the highest compared with the lowest risk quintile. The relative risk reduction with finerenone compared with placebo was consistent across the spectrum of risk for all outcomes examined (eg, interaction P value for primary outcome = .24). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: Results of the FINEARTS-HF randomized clinical trial demonstrate that the PREDICT-HFpEF models performed well in terms of calibration and discrimination. Baseline risk did not modify the benefit of finerenone. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40042880/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">40042880</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11883611/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250307091038&v=2.18.0.post9+e462414">PMC11883611</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2025.0025>10.1001/jamacardio.2025.0025</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40042880</guid><pubDate> Wed, 05 Mar 2025 06:00:00 -0500</pubDate><dc:creator> Kirsty McDowell</dc:creator><dc:creator> Kieran F Docherty</dc:creator><dc:creator> Ross T Campbell</dc:creator><dc:creator> Alasdair D Henderson</dc:creator><dc:creator> Pardeep S Jhund</dc:creator><dc:creator> Brian L Claggett</dc:creator><dc:creator> Akshay S Desai</dc:creator><dc:creator> James Lay-Flurrie</dc:creator><dc:creator> Lucas Hofmeister</dc:creator><dc:creator> Andrea Scalise</dc:creator><dc:creator> Carolyn SP Lam</dc:creator><dc:creator> Mark C Petrie</dc:creator><dc:creator> Morten Schou</dc:creator><dc:creator> Michele Senni</dc:creator><dc:creator> Sanjiv J Shah</dc:creator><dc:creator> Jacob A Udell</dc:creator><dc:creator> Faiez Zannad</dc:creator><dc:creator> Bertram Pitt</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:creator> Scott D Solomon</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:date> 2025-03-05</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF</dc:title><dc:identifier> pmid:40042880</dc:identifier><dc:identifier> pmc:PMC11883611</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2025.0025</dc:identifier></item></channel></rss>